文献速递儿童呼吸儿童感染新生儿

Clesrovimab在两个RSV seasons中对重症风险婴儿的随机临床试验

Clesrovimab in Infants at Increased Risk For Severe Disease During 2 RSV Seasons: A Randomized Clinical Trial.
PubMed 文献 · JAMA Pediatr · 2026-01-01

SMART试验在110个中心纳入997名符合帕利珠单抗条件的婴儿,随机接受Clesrovimab 105 mg或帕利珠单抗。第一季不良事件比例相当,RSV相关下呼吸道感染发生率分别为3.2%和3.4%。第二季210 mg耐受良好,支持高风险儿童第二季使用。

要点

  • Clesrovimab 105 mg第一季安全性与帕利珠单抗相当。
  • 第一季RSV相关MALRI发生率3.2% vs 3.4%。
  • 第二季210 mg耐受良好,支持继续使用。

核心结论

  • Clesrovimab在两个RSV seasons中对重症风险婴儿耐受良好。
  • 结果支持在第二季仍高风险儿童中使用Clesrovimab。

研究设计与样本

  • SMART为随机、部分设盲、帕利珠单抗对照的3期试验,在27个国家110个中心开展。
  • 997名婴儿随机1:1接受Clesrovimab 105 mg或帕利珠单抗15 mg/kg,第二季276名接受开放标签Clesrovimab 210 mg。

主要发现

  • 第一季两组不良事件比例相当。
  • 第一季Clesrovimab组RSV相关MALRI发生率为3.2%(95%CI 1.8%-5.2%),帕利珠单抗组为3.4%(95%CI 2.0%-5.6%)。
  • 第二季210 mg后180天内RSV相关MALRI总发生率为7.3%(95%CI 4.4%-11.4%)。

临床怎么用

  • 对于符合帕利珠单抗条件的重症RSV风险婴儿,可考虑使用Clesrovimab 105 mg预防第一季RSV疾病。
  • 对于第二季仍高风险儿童,可考虑使用Clesrovimab 210 mg。

局限性

  • 原文未报告具体局限性描述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Clesrovimab is a long-acting monoclonal antibody approved for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season; data concerning clesrovimab from a second RSV season among children who remain at risk for severe disease are needed. OBJECTIVE: To evaluate the safety and tolerability of clesrovimab (105 mg) vs palivizumab in RSV season 1 in infants at increased risk for severe RSV disease. Key secondary objectives include describing the safety of 210 mg of clesrovimab in RSV season 2 in children who remain at increased risk for severe RSV disease, clesrovimab pharmacokinetics, and the incidence of RSV-associated disease. DESIGN, SETTING, AND PARTICIPANTS: SMART (MK-1654-007) was a randomized, partially masked, palivizumab-controlled, phase 3 clinical trial, conducted at 110 sites in 27 countries and territories between November 30, 2021, and November 20, 2025. The population constituted palivizumab-eligible infants, including those with prematurity, chronic lung disease of prematurity, or hemodynamically significant congenital heart disease. INTERVENTIONS: Participants, randomized 1:1 and stratified by region and condition, received clesrovimab (105 mg) on day 1 followed by placebo on day 28 or monthly palivizumab (15 mg/kg) up to 5 doses (1 dose per month). Eligible infants received open-label clesrovimab (210 mg) before their second RSV season. MAIN OUTCOMES AND MEASURES: The primary outcome was the observed proportions of participants experiencing adverse events (AEs) after clesrovimab or palivizumab in season 1. RESULTS: Overall, 997 infants (500 [50.2%] male; median age, 2.6 [range, 0.0-12.0] months) received clesrovimab, 105 mg (n = 498) or palivizumab (n = 499) in season 1; 276 received clesrovimab, 210 mg open-label in season 2. In season 1, the proportions of participants experiencing AEs were comparable between treatment groups. In season 2, clesrovimab, 210 mg was well tolerated. Incidence rates of RSV-associated medically attended lower respiratory infection (MALRI) were comparable between clesrovimab and palivizumab (3.2% [95% CI, 1.8%-5.2%] and 3.4% [95% CI, 2.0%-5.6%], respectively) through day 150 in season 1; total RSV-associated MALRI incidence through day 180 after a 210-mg dose in season 2 was 7.3% (95% CI, 4.4%-11.4%). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, clesrovimab was well tolerated in infants at increased risk for severe RSV disease through 2 RSV seasons. These findings support the use of clesrovimab in children who remain at risk for severe RSV disease in their second RSV season. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04938830.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. Zar HJ, Bont LJ, Manzoni P, et al. Clesrovimab in Infants at Increased Risk For Severe Disease During 2 RSV Seasons: A Randomized Clinical Trial. JAMA Pediatr. 2026. PMID: 42475081. doi:10.1001/jamapediatrics.2026.2760

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。